Department of Laboratory Medicin, Tumour Biology, Lund University, Malmö University Hospital, Malmö, Sweden.
Prostate. 2010 Oct 1;70(14):1491-500. doi: 10.1002/pros.21184.
Interleukin-6 (IL-6) is a multifunctional cytokine that has been implicated in the modulation of growth and progression of prostate cancer. Decreased expression of the tyrosine phosphatase SHP-1, involved in regulation of cytokine and tyrosine kinase receptor signaling, has been shown to be associated with less favorable outcome among prostate cancer patients.
Parental LNCaP cells and an LNCaP-IL6+ subline, derived from parental LNCaP cells by continuous culture of the cells in the presence of recombinant IL-6 were used in the study. Expression of STAT3, pSTAT3, ERK, pERK, AKT, pAKT, PTEN, and SHP-1 was analyzed by immunohistochemistry, Western blots, cDNA microarray, quantitative PCRs, and reverse transcriptase PCRs. Proliferation and apoptosis of transfected cells were analyzed by caspase3/7 assay and flow cytometry.
Phosphorylation of ERK and STAT3 was increased in the LNCaP-IL6+ subline compared with LNCaP cells, whereas pAKT was decreased. Overexpression and inhibition experiments with SHP-1 siRNA showed that SHP-1 reduced proliferation and increased apoptosis in both cell lines. Microarray analysis revealed 80 up-regulated and 87 down-regulated SHP-1-related genes in the LNCaP-IL6+ cell line compared with LNCaP cells.
SHP-1 suppresses growth and increases apoptosis in both LNCaP and LNCaP-IL6+ cells, which suggests that SHP-1 could be a therapeutic target in prostate cancer, even when there is an IL-6-related growth advantage.
白细胞介素 6(IL-6)是一种多功能细胞因子,它参与调节前列腺癌的生长和进展。酪氨酸磷酸酶 SHP-1 的表达减少,该酶参与细胞因子和酪氨酸激酶受体信号的调节,已经表明与前列腺癌患者预后较差相关。
本研究使用亲本 LNCaP 细胞和源自亲本 LNCaP 细胞的 LNCaP-IL6+亚系,该亚系通过在存在重组 IL-6 的情况下连续培养细胞而产生。通过免疫组织化学、Western blot、cDNA 微阵列、定量 PCR 和逆转录 PCR 分析 STAT3、pSTAT3、ERK、pERK、AKT、pAKT、PTEN 和 SHP-1 的表达。通过 caspase3/7 测定和流式细胞术分析转染细胞的增殖和凋亡。
与 LNCaP 细胞相比,LNCaP-IL6+亚系中 ERK 和 STAT3 的磷酸化增加,而 pAKT 减少。SHP-1 的过表达和抑制实验表明,SHP-1 减少了这两种细胞系的增殖并增加了凋亡。微阵列分析显示,与 LNCaP 细胞相比,LNCaP-IL6+细胞系中有 80 个上调和 87 个下调的 SHP-1 相关基因。
SHP-1 抑制 LNCaP 和 LNCaP-IL6+细胞的生长并增加凋亡,这表明 SHP-1 可能是前列腺癌的治疗靶点,即使存在与 IL-6 相关的生长优势。